Your session is about to expire
← Back to Search
SABR for Lung Cancer (SUPPRESS-NSCLC Trial)
SUPPRESS-NSCLC Trial Summary
This trial is testing whether a new cancer treatment is better than the current standard of care.
SUPPRESS-NSCLC Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSUPPRESS-NSCLC Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2007 Phase 4 trial • 552 Patients • NCT00110890SUPPRESS-NSCLC Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread to my spine or digestive system.My cancer has spread to 1-5 spots outside the brain, affecting up to 3 organs, and is under 5cm.My cancer has spread in a limited way while on immunotherapy or targeted therapy.I had treatments like radiation or surgery for cancer spread before my current treatment.I am registered in the CRCHUM Lung Cancer and PERa registries with metastatic NSCLC.My cancer can be safely targeted with SABR according to my doctor.I have brain metastasis but it's being treated according to standard care.I am 18 years old or older.I can care for myself but may not be able to do heavy physical work.I have a tumor larger than 5 cm.
- Group 1: Standard of care
- Group 2: Experimental SABR arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the desired outcome of this investigation?
"This research study will assess the primary objective of Overall Survival (OS) over a five-year period. Secondary outcomes include Local Control, Quality of Life assessed using the EQ-5D-5L questionnaire and FACT-G tool, as well as CTCAE Patient Reported Outcomes measured with the PRO-CTCAE method."
What is the aggregate number of participants enrolled in this experiment?
"Affirmative, the details on clinicaltrials.gov verify that this research is presently recruiting participants. This trial was first published on May 1st 2021 and last edited on April 24th 2022. 68 volunteers must be enrolled across one medical facility."
Are new participants being admitted to this trial presently?
"Indeed, records on clinicaltrials.gov demonstrate that this trial is still recruiting participants and has been since January 5th 2021. With only 68 subjects required from a single location, the recruitment process should be brief."
Is the conventional treatment protocol sanctioned by the FDA?
"Safety data for Standard of Care was assessed to be a 2 as it is only currently being studied in Phase 2 trials; there are indications that the treatment may be safe, but efficacy has yet to be established."
Share this study with friends
Copy Link
Messenger